Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Molecular Predictors of Lung Cancer Behavior. (SPORE)

Multiple Cancer Types

Lung, Non Small Cell, Small Cell
N/A
Massion, Pierre
NCT00898313
VICCTHO0398

Molecular Fingerprinting of Lung Cancer (SPORE)

Multiple Cancer Types

Lung, Non Small Cell
N/A
Massion, Pierre
NCT00897117
VICCTHO0136

Nashville Biosciences Blood Sample Collection Study

Multiple Cancer Types

Colon, Liver, Lung, Non Small Cell, Ovarian, Pancreatic, Rectal
N/A
Bernard, Gordon
VICCMD18123

Treatment Patterns, Mechanisms of Resistance and Outcomes among Patients with EGFR Mutated Non-Small Cell Lung Cancer Treated with Osimertinib: An ATOMIC Consortium Analysis

Multiple Cancer Types

Lung, Non Small Cell
N/A
Horn, Leora
VICCTHO1916

Clinical Outcomes of Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer: An ATOMIC Consortium Analysis

Multiple Cancer Types

Lung, Non Small Cell
N/A
Iams, Wade
VICCTHO19141

LUNGMAP: A Master Protocol to Evaluate Biomarker Driven Therapies and Immunotherapies in Previously-treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Multiple Cancer Types

Lung, Non Small Cell
N/A
York, Sally
ECOGTHOS1900

Early Onset Pulmonary Events in Patients with Non-Small Lung Cancer or Other Cancers Taking Brigatinib or Other TKIs

Multiple Cancer Types

This phase II trial studies early onset pulmonary events in patients with non-small lung cancer and other cancers taking brigatinib or other TKIs. Severe side effects, including trouble breathing, coughing, pneumonia, and inflammation of the lungs (pneumonitis), have been seen in patients taking brigatinib. This study is being done to watch patients taking brigatinib and compare that experience with patients taking other drugs that also target ALK or ROS1 to study how often events like these occur. This study is also being done to observe patients who stopped brigatinib temporarily because of a suspected early onset pulmonary event, but then restarted brigatinib at the same dose to assess what experience they have.
Lung, Non Small Cell
II
Iams, Wade
NCT03389399
VICCTHO1885

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Multiple Cancer Types

This phase III ALCHEMIST trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Lung, Non Small Cell
III
York, Sally
NCT02201992
ECOGTHOE4512

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Multiple Cancer Types

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.
Lung, Non Small Cell
III
York, Sally
NCT03793179
ECOGTHOEA5163

Screening Methods for Early Diagnosis of Lung Cancer in Current or Former Smokers

Multiple Cancer Types

This trial studies methods of detecting lung cancer at an earlier stage in current or former smokers with a special type of computed tomography (CT) scan and by testing genes and proteins in biospecimens (blood, urine, sputum, and tissue samples) collected at the time of bronchoscopy (examination of the airway). Analyzing these methods may provide an early detection of lung cancer in current or former smokers when it is more amenable to a cure.
Lung, Miscellaneous, Non Small Cell
N/A
Massion, Pierre
NCT01475500
VICCTHO1078

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: